RxDoctor Payments Data

Thompson Liddell, MD

Infectious Disease · Hattiesburg, MSNPI 1851703201

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Viiv Healthcare Company at 38.6% of the total.

$1,973in general payments, 2019–2025

Across 118 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$762
  • Gilead$538
  • Merck$186
  • Insmed, Inc.$162
  • AbbVie$118
  • Johnson & Johnson$45
  • plus $161 from 7 others

What the payments were for

  • Food & beverage$1,92498%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,973 in reported general payments places this provider in the 85th percentile of 36 infectious disease providers in Mississippi.

See all infectious disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$94,211
Medicare patients
278
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala68$267,936
DovatoDolutegravir Sodium/Lamivudine60$172,716
TivicayDolutegravir Sodium18$68,041
Daptomycin72$54,039
JulucaDolutegravir/Rilpivirine12$44,294
DescovyEmtricitabine/Tenofov Alafenam18$36,418
ErtapenemErtapenem Sodium77$30,317
Vancomycin Hcl154$12,240
Meropenem41$6,868
Ethambutol Hcl75$4,171
Rifampin73$3,865
Azithromycin110$3,541
CeftriaxoneCeftriaxone Sodium113$3,449
Sodium Chloride0.9 % Sodium Chloride374$3,007
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod41$2,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$538$304,35486 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca$762$285,05290 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 36 infectious disease providers in Mississippi.

Other infectious disease in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →